Cargando…
Serum-Dependence of Affinity-Mediated VEGF Release from Biomimetic Microspheres
[Image: see text] Vascular endothelial growth factor (VEGF) activity is highly regulated via sequestering within the ECM and cell-demanded proteolysis to release the sequestered VEGF. Numerous studies have demonstrated that VEGF activity mediates cellular events leading to angiogenesis and capillary...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American
Chemical Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059260/ https://www.ncbi.nlm.nih.gov/pubmed/24773176 http://dx.doi.org/10.1021/bm500177c |
_version_ | 1782321222165463040 |
---|---|
author | Belair, David G. Khalil, Andrew S. Miller, Michael J. Murphy, William L. |
author_facet | Belair, David G. Khalil, Andrew S. Miller, Michael J. Murphy, William L. |
author_sort | Belair, David G. |
collection | PubMed |
description | [Image: see text] Vascular endothelial growth factor (VEGF) activity is highly regulated via sequestering within the ECM and cell-demanded proteolysis to release the sequestered VEGF. Numerous studies have demonstrated that VEGF activity mediates cellular events leading to angiogenesis and capillary formation in vivo. This has motivated the study of biomaterials to sustain VEGF release, and in many cases, the materials are inspired by the structure and function of the native ECM. However, there remains a need for materials that can bind to VEGF with high specificity, as the in vivo environment is rich in a variety of growth factors (GFs) and GF-binding moieties. Here we describe a strategy to control VEGF release using hydrogel microspheres with tethered peptides derived from VEGF receptor 2 (VEGFR2). Using biomaterials covalently modified with varying concentrations of two distinct VEGFR2-derived peptides with varying serum stability, we analyzed both biomaterial and environmental variables that influence VEGF release and activity. The presence of tethered VEGF-binding peptides (VBPs) resulted in significantly extended VEGF release relative to control conditions, and the resulting released VEGF significantly increased the expansion of human umbilical vein endothelial cells in culture. VEGF release rates were also strongly influenced by the concentration of serum. The presence of Feline McDonough Sarcoma-like tyrosine kinase 1 (sFlt-1), a serum-borne receptor fragment derived from VEGF receptor 1, increased VEGF release rates, although sFlt-1 was not sufficient to recapitulate the release profile of VEGF in serum. Further, the influence of serum on VEGF release was not due to protease activity or nonspecific VEGF interactions in the presence of serum-borne heparin. VEGF release kinetics correlated well with a generalizable mathematical model describing affinity-mediated release of VEGF from hydrogel microspheres in defined conditions. Modeling results suggest a potential mechanism whereby competition between VEGF and multiple VEGF-binding serum proteins including sFlt-1, soluble kinase insert domain receptor (sKDR), and α2-macroglobulin (α2-M) likely influenced VEGF release from microspheres. The materials and mathematical model described in this approach may be useful in a range of applications in which sustained, biologically active GF release of a specific GF is desirable. |
format | Online Article Text |
id | pubmed-4059260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | American
Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-40592602015-04-29 Serum-Dependence of Affinity-Mediated VEGF Release from Biomimetic Microspheres Belair, David G. Khalil, Andrew S. Miller, Michael J. Murphy, William L. Biomacromolecules [Image: see text] Vascular endothelial growth factor (VEGF) activity is highly regulated via sequestering within the ECM and cell-demanded proteolysis to release the sequestered VEGF. Numerous studies have demonstrated that VEGF activity mediates cellular events leading to angiogenesis and capillary formation in vivo. This has motivated the study of biomaterials to sustain VEGF release, and in many cases, the materials are inspired by the structure and function of the native ECM. However, there remains a need for materials that can bind to VEGF with high specificity, as the in vivo environment is rich in a variety of growth factors (GFs) and GF-binding moieties. Here we describe a strategy to control VEGF release using hydrogel microspheres with tethered peptides derived from VEGF receptor 2 (VEGFR2). Using biomaterials covalently modified with varying concentrations of two distinct VEGFR2-derived peptides with varying serum stability, we analyzed both biomaterial and environmental variables that influence VEGF release and activity. The presence of tethered VEGF-binding peptides (VBPs) resulted in significantly extended VEGF release relative to control conditions, and the resulting released VEGF significantly increased the expansion of human umbilical vein endothelial cells in culture. VEGF release rates were also strongly influenced by the concentration of serum. The presence of Feline McDonough Sarcoma-like tyrosine kinase 1 (sFlt-1), a serum-borne receptor fragment derived from VEGF receptor 1, increased VEGF release rates, although sFlt-1 was not sufficient to recapitulate the release profile of VEGF in serum. Further, the influence of serum on VEGF release was not due to protease activity or nonspecific VEGF interactions in the presence of serum-borne heparin. VEGF release kinetics correlated well with a generalizable mathematical model describing affinity-mediated release of VEGF from hydrogel microspheres in defined conditions. Modeling results suggest a potential mechanism whereby competition between VEGF and multiple VEGF-binding serum proteins including sFlt-1, soluble kinase insert domain receptor (sKDR), and α2-macroglobulin (α2-M) likely influenced VEGF release from microspheres. The materials and mathematical model described in this approach may be useful in a range of applications in which sustained, biologically active GF release of a specific GF is desirable. American Chemical Society 2014-04-29 2014-06-09 /pmc/articles/PMC4059260/ /pubmed/24773176 http://dx.doi.org/10.1021/bm500177c Text en Copyright © 2014 American Chemical Society |
spellingShingle | Belair, David G. Khalil, Andrew S. Miller, Michael J. Murphy, William L. Serum-Dependence of Affinity-Mediated VEGF Release from Biomimetic Microspheres |
title | Serum-Dependence of Affinity-Mediated VEGF Release
from Biomimetic Microspheres |
title_full | Serum-Dependence of Affinity-Mediated VEGF Release
from Biomimetic Microspheres |
title_fullStr | Serum-Dependence of Affinity-Mediated VEGF Release
from Biomimetic Microspheres |
title_full_unstemmed | Serum-Dependence of Affinity-Mediated VEGF Release
from Biomimetic Microspheres |
title_short | Serum-Dependence of Affinity-Mediated VEGF Release
from Biomimetic Microspheres |
title_sort | serum-dependence of affinity-mediated vegf release
from biomimetic microspheres |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059260/ https://www.ncbi.nlm.nih.gov/pubmed/24773176 http://dx.doi.org/10.1021/bm500177c |
work_keys_str_mv | AT belairdavidg serumdependenceofaffinitymediatedvegfreleasefrombiomimeticmicrospheres AT khalilandrews serumdependenceofaffinitymediatedvegfreleasefrombiomimeticmicrospheres AT millermichaelj serumdependenceofaffinitymediatedvegfreleasefrombiomimeticmicrospheres AT murphywilliaml serumdependenceofaffinitymediatedvegfreleasefrombiomimeticmicrospheres |